Techniques in Orthopaedics published an article examining MiMedx Group's dehydrated human aminon/chorion membrane allografts for orthopedic applications.
More than 226 growth factors and bioactive proteins are identified to date in the dHACM allografts that are shown to regulate activity for a variety of cell types. The company's allografts are used for a variety of orthopedic procedures, including joint space disorders and spine surgeries.
In the spine space, dHACM has been used during transforaminal lumbar interbody fusion to minimize postlaminectomy epidural adhesions and scarring. The result has been lower pain scores.
The study found dHACM allografts modulated three main phases of healing, including inflammation, proliferation and remodeling. "Clinical usage in orthopedic repair is rapidly growing," said President and COO Bill Taylor. The company plans to further test the clinical efficiency of dHACM in microdiscectomy, lumbar decompressions and total knee replacements.